Calcineurin inhibitors such as tacrolimus have well-recognized efficacy in organ transplantation but side effects of nephrotoxicity, neurotoxicity, and β-cell toxicity that can be particularly detrimental in islet transplantation. Neuro-and nephrotoxicity have been demonstrated in multiple islet transplant recipients despite the relatively low serum maintenance levels typically used (3-5 ng/ml). We describe a single patient in whom symptoms and signs of neurotoxicity necessitated substitution of tacrolimus with mycophenolate mofetil (MMF), which resulted in complete symptom resolution over the subsequent 9 months. Concomitantly noted were an almost immediate improvement in glycemic control and an improved response to stimulation testing, suggesting remission of tacrolimus-induced β-cell toxicity and insulin resistance. At 18 months post-"switch," 30 months posttransplant, the patient remains insulin independent with good glycemic control. The goal to remove calcineurin inhibitors from regimens of islet transplantation is a worthy one.
INTRODUCTION
going islet transplantation alone due to the risk of precipitating premature renal failure in patients with diabetic nephropathy. In islet transplantation, subjects with Success in islet transplantation using the Edmonton protocol of immunosuppression has been reproduced at normal renal function are less likely to develop complications; those with elevated serum creatinine, albumin-centers around the world, including this one (1, 6, 9, 11, 14) . This novel immunosuppressive regimen consists of uria, or proteinuria are likely to progress (10, 20, 21) . Neurotoxicity has been reported in more than 80% of high-dose sirolimus (Rapamune, Wyeth-Ayerst, USA) and low-dose tacrolimus (Prograf, Fujisawa, USA) in recipients (10) . Although typically mild and not life threatening, it can be most difficult for the patient to the absence of steroids (20) (21) (22) . It was hoped that the relatively low serum levels of tacrolimus (3-5 ng/ml) bear on a daily basis, has the potential to be severe, and in solid organ transplantation sometimes irreversible used would avoid the well-recognized side effects of nephrotoxicity (16) and neurotoxicity (3,24). However, (3, 23) . The well-recognized diabetogenic effects of tacroli-it appears that in combination with sirolimus there is a synergistic effect resulting in side effect rates similar to mus are highly undesirable in a situation where the transplanted mass of islets is marginal in many recipi-higher levels of tacrolimus alone. For this reason, the search for drug combinations with improved side effect ents and where long-term survival and function of islets may be affected, limiting duration of insulin indepen-profiles and greater long-term efficacy continues, despite the demonstrated efficacy of this regimen. dence. In solid organ transplantation using tacrolimusbased immunosuppressive regimens, the incidence of Nephrotoxicity is a serious concern in patients under-614 FROUD ET AL.
posttransplant diabetes mellitus varies according to
Glycemic control was assessed by daily fingerstick blood glucose (FSG) testing using a precision gluco-definition but is in the range of 30% (12, 13) and the diabetogenicity of the drug has been clearly reported meter (MediSense, Abbott, USA); these values were entered by the patient into the Humalink TM system, a com-even at low, maintenance doses (5). In islet transplant recipients, this phenomenon may have remained unrec-puterized remote telephone access database (15), which was recently modified to calculate the mean amplitude ognized as decreased graft function may be more readily ascribed to low engrafted mass, islet denerva-of glycemic excursions (MAGE) at monthly intervals. Graft function was assessed with biweekly serum glu-tion, intrahepatic location, and/or posttransplant islet losses of any etiology.
cose and c-peptide levels every 2-4 weeks, monthly glycosylated hemoglobin (A1c), and quarterly stimulation While tacrolimus may be beneficial for islet engraftment, its removal during follow-up may be beneficial testing, using mixed meal, intravenous glucose, and arginine stimulation. Continuous glucose monitoring sens-for improved long-term islet survival and function. Mycophenolate mofetil (MMF) is the next drug of choice ing (CGMS) (MiniMed, USA) was obtained pre-and post-MMF conversion; data were analyzed by the Med-and in combination with sirolimus may represent an alternative regimen. The patient described herein had tronic Minimed Solutions Software version 3.0A (8) .
Medical history, physical examination, and psycho-signs and symptoms of neurotoxicity that resulted in the decision to remove tacrolimus and replace it with logical evaluation are performed routinely at selected intervals posttransplant in all recipients. Neurotoxicity was MMF in spite of the risk of complete graft loss. The subsequent improvement in graft function supports the further evaluated by a neurologist with electroencephalogram (EEG) and magnetic resonance imaging (MRI). hypothesis of unrecognized tacrolimus β-cell toxicity and supports the concept of a reversible, dose-related Results are given as means ± SD. Data were analyzed with Statistica for Windows software (Statsoft, Tulsa, diabetogenic effect of the drug as previously reported (19) .
OK) using one-way analysis of variance. All comparisons were considered statistically significant at p < 0.05.
MATERIALS AND METHODS RESULTS
The patient is a 32-year-old female with 19 years of type 1 diabetes mellitus (T1DM) complicated by stable
The patient received 8476 islet equivalents/kilogram body weight (IEQ/kg), total 576367 IEQ with the first proliferative retinopathy, hypoglycemia unawareness, and unstable glycemic control despite intensive treat-infusion and 4848 IEQ/kg, total 324787 IEQ with the second infusion performed 6 weeks later, for a total of ment. At the time of initial transplant, she weighed 68 kg (149 lbs), BMI 25, and an insulin requirement of 35 13324 IEQ/kg, 901154 IEQ. A reduction in exogenous insulin requirement of 56% was noted after the first in-units daily (0.5 U/kg/24 h). The protocol was approved by the Medical Sciences Subcommittee for the Protec-fusion; insulin independence was achieved immediately following the second infusion. No complications were tion of Human Subjects in Research at the University of Miami, School of Medicine. The source of islets was observed from either transplant procedure. Two months after commencing immunosuppressive brain-dead, heart-beating multiorgan donors and islets were prepared and transplanted as previously described therapy, the patient complained of insomnia and headache, not typical of migraine. One month later she was (2,7,18).
Immunosuppression was commenced on postopera-experiencing nightmares, confusion, apprehension, and episodes of memory lapses, grade 2 in severity accord-tive day (POD) −1. Induction consisted of five doses of daclizumab (Zenapax, Roche, USA) 1 mg/kg given at ing to National Cancer Institute (NCI) criteria (Common Terminology Criteria for Adverse Events v3.0). Head-two weekly intervals; thereafter, daclizumab infusions were continued at monthly intervals for 1 year, every ache responded to treatment with analgesia and nortriptyline, insomnia to temazepam, and she adjusted to two months for a second year, and then discontinued. Maintenance immunosuppression consisted of sirolimus, symptoms. During psychological evaluation at 5 months post-initial infusion, the patient complained of persistent serum levels of 12-15 ng/ml for 3 months, 8-10 ng/ml thereafter, and tacrolimus, serum levels of 3-5 ng/ml insomnia, limited energy, decreased concentration, and memory lapses, still present at 8 months posttransplant. indefinitely. A single dose of infliximab (Remicade, Centocor) 5 mg/kg IV was administered 1 h pretrans-No deficit could be detected during limited memory testing. At 9 months (281 days post-initial infusion) the pa-plant to facilitate engraftment. Other medications introduced at the time of transplantation included gancyclovir tient complained of worsening of memory symptomatology, the severity of which became evident when the (Cytovene, Roche, USA), pentoxifylline (Trental, Aventis, USA), trimethoprim-sulfamethoxazole (Bactrim, patient described running out of space to write reminders on both hands and both feet (NCI grade 3). This Hoffman-La Roche, Inc.), and vitamins A, B 6 , C, and E. prompted a brain MRI scan, which demonstrated multi-memory was back to normal and she no longer experienced insomnia, headache, confusion, nightmares, or ap-ple small nonspecific punctuate foci of high T2 signal in the periatrial white matter of both parieto-occipital prehension. Repeat MRIs of the brain at 4 and 11 months post-switch were minimally improved. hemispheres greater than expected for a patient of this age (Fig. 1) . Differential diagnosis included small vessel FSG pre-and postprandial values demonstrated significant decrease of 5% and 10%, respectively, compar-ischemic changes, connective tissue disorder such as systemic lupus erythematosis, multiple sclerosis, migraine-ing 3 months pre-and post-switch (Fig. 2) . MAGE value pre-and post-MMF conversion were 43 ± 23 mg/dl (n = related changes, postinfectious demyelination, and tacrolimus-induced neurotoxicity. 41) and 28 ± 9 mg/dl (n = 5), respectively (NS). Fasting c-peptide levels decreased slightly from 2.3 ± 0.5 ng/ml Testing for CMV, HSV, VZV, parvovirus B19, syphilis, and Lyme disease were negative. Titers for ANA, (n = 7) to 2.0 ± 0.5 ng/ml (n = 6) (NS), while the c-peptide glucose ratio remained essentially unchanged: 1.91 ± 0.2 C3, C5, and CH50 were normal. There was no documented hypertension. Lipid levels rose at 9 months post-(n = 7) to 1.82 ± 0.4 (n = 6) (NS). Arginine stimulation testing showed a significant in-transplant, peak total cholesterol 289 mg/dl, LDL cholesterol 190 mg/dl (NCI grade 1), normalizing over 4 crease in insulin release (AIRarg) from mean 12.2 ± 4.6 (n = 3) to 24.3 ± 3.0 uIU/ml (n = 3) (p = 0.011) ( Fig. 3 ). months following introduction of atorvastatin. Liver transaminases remained minimally elevated (NCI grade During intravenous glucose tolerance testing (IVGTT), AIRgluc improved slightly from 23.7 ± 3.5 (n = 3) to 1) for 5 months following the final infusion and subsequently remained normal. Thyroid function and renal 26.8 ± 2.5 uIU/ml (n = 4) (NS). Mixed meal testing was unchanged. A1c decreased slightly from 6.0 ± 0.2 (n = function remained normal.
Neurological consultation was sought; EEG was 4) to 5.9 ± 0.3% (n = 6) (NS) (Fig. 4) . Homeostasis model assessment (HOMA), calculated from baseline markedly abnormal with generalized "slowing" of electrical activity likely secondary to tacrolimus-induced values of IVGTT [(insulin µIU/ml × glucose mmol)/ 22.5] demonstrated a persistent decrease following ces-neurotoxicity. The decision was made to substitute this medication with MMF for maintenance immunosuppres-sation of tacrolimus from mean 1.8 ± 0.52 (n = 3) to mean 0.8 ± 0.08 (n = 5) (p = 0.004) (Fig. 5 ). sive therapy. At 312 days posttransplant, MMF was commenced at 500 mg BID and increased to 1 g BID CGMS 72-h tracings showed significant glycemic peaks and fluctuations over 200 mg/dl pre-MMF con-over 8 days, with concomitant decrease of tacrolimus by 0.5 mg every 2 days until discontinued on POD 320.
version in contrast to normoglycemic tracings of 100-140 mg/dl postconversion without any change in diet, Clinical symptoms improved gradually over the next weeks to months. By 4 months following the switch, the activity, or body weight (Fig. 6) . The patient is currently 39 months posttransplant, 30 EEG had normalized and the patient stated that she felt her memory had improved; by 8 months, she felt her months post-MMF conversion, and remains insulin inde- pendent. Usual MMF side effects, such as leukopenia (e.g., cyclosporine conventional formulation vs. microemulsion), route of administration (oral vs. intravenous), and diarrhea, have not been observed. and comorbidities such as advanced liver failure, hyper-DISCUSSION tension, hypocholesterolemia, hypomagnesemia, and methylprednisolone administration may predispose to Since the introduction of tacrolimus in the 1990s, its efficacy as an immunosuppressive agent has surpassed neurotoxicity. In its milder form, symptoms include tremor, insomnia, nightmares, headache, vertigo, dyses-that of cyclosporine; however, a higher incidence of neurotoxic adverse effects has also been observed (25) . thesia, photophobia, memory loss, or mood disturbance. However, in up to 5% of patients with neurotoxicity, a More frequently associated with higher immunosuppressant levels, this is not universal, and drug formulation leukoencephalopathy can develop in which patients ex- hibit severe neurological symptoms ranging from corti-evaluation and the generalized slowing of brain waves on EEG supported the clinical diagnosis and were in-cal blindness, visual field defects, motor and sensory deficits, agitation, lethargy, confusion, seizures, and death. strumental in the decision to remove tacrolimus as no other etiology for the EEG abnormalities could be iden-While effects are reversible in the majority of patients with reduction or removal of the medication, some pa-tified and the concern of progression or lack of reversibility of neurotoxicity. While the MRI abnormalities tients have experienced permanent disability (3,23).
The described patient complained of a symptomatol-were not characteristic and its subsequent lack of resolution suggested that these were not related to the adverse ogy constellation that left little doubt she was clinically experiencing tacrolimus neurotoxicity; the compromise events described, there was initial concern that the imaging findings could represent an early subacute stage of short-term memory was perhaps most intrusive due to her high level of functioning. Further neurological of tacrolimus-induced encephalopathy.
Tacrolimus-induced β-cell toxicity is well described ticularly in islet transplantation where the entire graft can be lost secondary to a single immunological event. in solid organ transplantation, with a reported incidence of posttransplant diabetes mellitus of up to 30% (12, 13) , Because islet transplantation is not a life-saving procedure, however, there is lesser justification for potentially and β-cell toxicity has been demonstrated also in transplanted human islets (19) . Theories of tacrolimus-serious side effects. Symptom resolution and functional graft improvement support the notion that neurotoxicity induced β-cell toxicity include its effect on the synthesis/release of insulin and increased peripheral resistance. and β-cell toxicity were present; the latter has not previously been demonstrated in islet transplantation. It may also play a role in the gradual loss of islet mass seen over time in many islet transplant recipients and
In conclusion, tacrolimus toxicity can indeed be significant, even at the low levels used in the Edmonton may even reduce islet survival at the time of engraftment. Studies have suggested that tacrolimus reversibly protocol of immunosuppression. This may be in part due to the synergism between tacrolimus and sirolimus. Use inhibits insulin gene transcription, leading to a decline in insulin mRNA levels, insulin synthesis, and ultimately of MMF, with its lack of neurotoxic side effects and lack of β-cell toxicity, may translate to better duration insulin secretion (17) . Biopsies of patients with whole organ transplants have demonstrated a reduced number of graft survival and insulin independence. In this case, the typical side effects of MMF, namely leucopenia and of secretory granules in pancreatic β-cells, a histological finding that was reversible upon cessation of tacrolimus diarrhea, were not seen. MMF combined with sirolimus is an attractive regimen if proven to be effective in (4). In healthy dogs, tacrolimus has been demonstrated to cause delayed disappearance of glucose and reduced larger groups of patients. insulin secretion in response to intravenous glucose nine at hyperglycemic levels was diminished, suggesting a decrease in secretory reserve (5). REFERENCES In the patient described, the changes in graft function
